BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 30659154)

  • 21. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
    Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
    Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
    Stewart JH; Tran TL; Levi N; Tsai WS; Schrump DS; Nguyen DM
    J Surg Res; 2007 Jul; 141(1):120-31. PubMed ID: 17574045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.
    Volta V; Ranzato E; Martinotti S; Gallo S; Russo MV; Mutti L; Biffo S; Burlando B
    PLoS One; 2013; 8(3):e58051. PubMed ID: 23526965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
    Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
    Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
    Pozsgai E; Schally AV; Hocsak E; Zarandi M; Rick F; Bellyei S
    Int J Oncol; 2011 Oct; 39(4):1025-32. PubMed ID: 21701777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
    Takayama Y; Hattori N; Hamada H; Masuda T; Omori K; Akita S; Iwamoto H; Fujitaka K; Kohno N
    Cancer Res; 2016 Jun; 76(11):3285-94. PubMed ID: 27197170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
    Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
    Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
    [No Abstract]   [Full Text] [Related]  

  • 29. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.
    Schally AV; Wang H; He J; Cai R; Sha W; Popovics P; Perez R; Vidaurre I; Zhang X
    Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12028-12033. PubMed ID: 30373845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.
    Schally AV; Varga JL; Engel JB
    Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):33-43. PubMed ID: 18084344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of growth hormone-releasing hormone receptor splice variant 1 in primary human melanomas.
    Chatzistamou I; Volakaki AA; Schally AV; Kiaris H; Kittas C
    Regul Pept; 2008 Apr; 147(1-3):33-6. PubMed ID: 18255167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.
    Chaouche-Mazouni S; Copin MC; Lassalle P; Lebaili N; Cortot A; Scherpereel A
    In Vivo; 2013; 27(2):227-32. PubMed ID: 23422483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FK228 suppress the growth of human malignant pleural mesothelioma tumor independent to epithelioid or non-epithelioid histology.
    Chan JM; Chang YC; Chan HC; Chan HC; Chang WC; Wang LF; Tsai TH; Chen YJ; Huang WC
    Mol Med; 2024 May; 30(1):73. PubMed ID: 38822233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line.
    Annunziata M; Grande C; Scarlatti F; Deltetto F; Delpiano E; Camanni M; Ghigo E; Granata R
    Fertil Steril; 2010 Aug; 94(3):841-9. PubMed ID: 19524226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
    Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
    Jänne PA; Taffaro ML; Salgia R; Johnson BE
    Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
    Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
    Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
    Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
    Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
    Meerang M; Bérard K; Felley-Bosco E; Lauk O; Vrugt B; Boss A; Kenkel D; Broggini-Tenzer A; Stahel RA; Arni S; Weder W; Opitz I
    Mol Cancer Ther; 2016 May; 15(5):1095-105. PubMed ID: 26839306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
    Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
    J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.